IQVIA Holdings Inc. (IQV)
Automate Your Wheel Strategy on IQV
With Tiblio's Option Bot, you can configure your own wheel strategy including IQV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IQV
- Rev/Share 88.2015
- Book/Share 34.0637
- PB 4.1313
- Debt/Equity 2.4271
- CurrentRatio 0.8234
- ROIC 0.0814
- MktCap 24313420000.0
- FreeCF/Share 12.3108
- PFCF 11.2406
- PE 18.5104
- Debt/Assets 0.531
- DivYield 0
- ROE 0.2074
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IQV | HSBC Securities | Buy | Hold | -- | $160 | April 25, 2025 |
| Downgrade | IQV | Barclays | Overweight | Equal Weight | -- | $170 | April 10, 2025 |
| Downgrade | IQV | BTIG Research | Buy | Neutral | -- | -- | Feb. 3, 2025 |
| Initiation | IQV | Stephens | -- | Overweight | -- | $250 | Dec. 20, 2024 |
| Initiation | IQV | Redburn Atlantic | -- | Buy | -- | -- | Oct. 14, 2024 |
News
IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials
Published: May 16, 2025 by: Business Wire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners worldwide. By combining the capabilities of IQVIA and SCRI Development.
Read More
Investing in IQVIA (IQV)? Don't Miss Assessing Its International Revenue Trends
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
IQVIA: Q1 Earnings Support Steady Optimism
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Positive
IQVIA Holdings reported strong Q1 earnings with $3.83B in revenue, driven by growth in the Technology & Analytics Solutions segment, despite market pessimism. The company's profitability remains robust with adjusted EBITDA of $883M and a 6.3% increase in adjusted EPS, supported by high cash flow conversion. IQVIA's active share repurchase program and raised full-year revenue guidance highlight management's confidence in weathering sector volatility and macroeconomic headwinds.
Read More
IQVIA (IQV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
IQVIA Holdings Inc. (IQV) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
IQVIA Holdings Inc. (NYSE:IQV ) Q1 2025 Earnings Conference Call May 6, 2025 9:00 AM ET Company Participants Kerri Joseph - Senior Vice President, Investor Relations and Treasury Ari Bousbib - Chief Executive Officer Ron Bruehlman - Chief Financial Officer Mike Fedock - Senior Vice President, Financial Planning and Analysis Conference Call Participants Justin Bowers - Deutsche Bank Matthew Sykes - Goldman Sachs Shlomo Rosenbaum - Stifel Financial Corp. Michael Ryskin - Bank of America Jailendra Singh - Truist Securities Eric Coldwell - Robert W. Baird & Co. David Windley - Jefferies Group LLC Tejas Savant - Morgan Stanley Operator …
Read More
IQVIA Earnings & Revenues Beat Estimates in Q1, Increase Y/Y
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
IQV's top line in the first quarter of 2025 benefits from the Research and Development, and Technology and Analytics segments.
Read More
IQVIA Holdings (IQV) Surpasses Q1 Earnings and Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
IQVIA Holdings (IQV) came out with quarterly earnings of $2.70 per share, beating the Zacks Consensus Estimate of $2.63 per share. This compares to earnings of $2.54 per share a year ago.
Read More
IQVIA Reports First-Quarter 2025 Results
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended March 31, 2025. First-Quarter 2025 Operating Results Revenue for the first quarter of $3,829 million increased 2.5 percent on a reported basis and 3.5 percent at constant currency, compared to the first.
Read More
IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock?
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Growth across the R&DS and TAS segments is anticipated to have boosted IQV's top line in the first quarter of 2025.
Read More
IQVIA (IQV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of IQVIA (IQV) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
IQVIA (IQV) Moves 8.7% Higher: Will This Strength Last?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
IQVIA (IQV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Here's Why Investors Must Hold IQV Stock in Their Portfolios Now
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The IQV stock is benefiting from partner retention, acquisition and investment in AI-led innovation.
Read More
IQVIA Gains From Diversified Client Base Despite Low Liquidity Woes
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The IQV stock benefits from its healthcare-centric IT infrastructure across the globe and a treasure trove of data distinguishing it from its competitors.
Read More
IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy?
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
Read More
About IQVIA Holdings Inc. (IQV)
- IPO Date 2013-05-09
- Website https://www.iqvia.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Ari Bousbib
- Employees 89000